Orcosa Announces Two New Appointments to Board of Directors 

EWING, N.J. – January 30, 2024 – Orcosa Inc. (“Orcosa” or the “Company”), a clinical-stage life sciences company improving patient outcomes through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced the appointment of Edward A. Sturchio and Robert S. Radie to Orcosa’s Board of Directors, effective January 1, 2024. 

Mr. Sturchio has over 20 years working across the life sciences industry, including drug development and commercialization, regulatory compliance, corporate strategy and M&A. He is currently the General Counsel and an Executive Committee member of Immatics N.V. (Nasdaq: IMTX), an international immuno-oncology company. Mr. Radie brings more than three decades of experience working for both public and private pharmaceutical and biotech companies across a range of therapeutic areas. Currently, Mr. Radie is Chairman and Chief Executive Officer of Neuraptive Therapeutics, a leader in innovative medical solutions.

Collectively, Mr. Sturchio and Mr. Radie’s decades of leadership experience, and deep operational and legal expertise across the life sciences industry will bring valuable, independent perspectives and insights to the board and management team. 

“We are pleased to welcome Edward and Bob to our Board of Directors at such an important and exciting time for Orcosa,” said Bryan Ridall, Chairman, President and CEO of Orcosa. “They each bring a unique and independent voice to our Board, along with complementary skills, and deep industry connections, knowledge and experience. We are grateful for their commitment to Orcosa, and their passion for our mission to improve patient outcomes through our RITe™ Platform.”

Mr. Sturchio Biography

Mr. Sturchio is an accomplished life sciences executive, business strategist and advisor. Prior to his current role as General Counsel and Executive Committee member of Immatics N.V., he served as General Counsel and Senior Leadership member at Abeona Therapeutics and as Global General Counsel of Advanced Accelerator Applications (AAA), a Novartis company, where he was responsible for worldwide legal, compliance and IP functions across 22 sites in 13 countries. Before joining AAA, Mr. Sturchio worked in the Corporate Securities and Life Sciences departments of Greenberg Traurig LLP and Day Pitney LLP for over fifteen years, where he advised pharmaceutical and life sciences executives and boards of directors on regulatory, transactional, corporate strategy, M&A and securities matters.

He received a J.D. from Seton Hall University and a B.A. in psychology from Villanova University. Mr. Sturchio has written and lectured extensively in the areas of executive leadership, life sciences and corporate securities matters.

Mr. Radie Biography

Mr. Radie has more than three decades of experience working in both public and private pharmaceutical and biotech companies across a range of therapeutic areas. Prior to his current role as Chairman and CEO of Neuraptive Therapeutics, he served as President, CEO and Director of Zyla Life Sciences. His other roles across the life sciences industry include as President and CEO of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur, President and CEO of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, and Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick Pharmaceuticals, he served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company.

He currently serves as Chairman of the Board of Rockwell Medical, and as a member on the Board of Directors of Valsource, Inc. He also serves as Chairman of the Board at Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Previously, Mr. Radie served as a Director of Paratek Pharmaceuticals, Inc., Affinium Pharmaceuticals, Ltd. and Veloxis Pharmaceuticals AS.

Mr. Radie received his B.S. in Chemistry from Boston College.

About Orcosa Inc.

Orcosa is a life sciences company modernizing the way medicines are taken by combining cutting edge drug delivery with targeted therapeutics to improve patient outcomes. The company has developed the proprietary Rapid Infusion Technology (RITe™) Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa is building a robust pipeline of therapies utilizing the RITe™ Platform to provide transformative medicines for people with chronic and serious diseases. For more information on Orcosa, please visit https://www.orcosa.com.

Media Contact:


Investor Contact: